N/A N=67 WallFlex Pancreatic Metal Stent for Pancreatic Duct Strictures
Chronic Pancreatitis
Primary: Pain Reduction — 12 Participants — p=0.999
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=86 Bone Regenerative Techniques in Endodontic Microsurgery
Apical Periodontitis
Primary: 2D Radiographic Healing at 12 Months Follow up (Overall Cases) — 24; 29; 1; 1 osteotomy site
Phase 2 N=25 Levetiracetam in Early Psychosis
Psychosis · Schizophrenia · Schizo Affective Disorder
Primary: Change in Cerebral Blood Flow (CBF) — -2.21; -3.83; -1.29 mL / (100g * min)
N/A N=44 Graft-first Versus Fistula-first in Older Patients With End-stage Kidney Disease
Kidney Diseases
Primary: Feasibility- Eligibility for Randomization — 54 Participants
N/A N=109 Study of the Hummingbird TTS™ Tympanostomy Tube System
Otitis Media
Primary: Percentage of Procedures Converted From Sedation to General Anesthesia — 12.8 percentage of procedures converted
N/A N=80 Efficacy of inControl Advice: A Decision Support System (DSS) for Diabetes
Type1 Diabetes Mellitus
Primary: % Time Within Target Range — 57.7; 58.2 percentage of time in range
N/A N=119 Development and Testing of a Just-in-Time Adaptive Smart Phone Intervention to Reduce Drinking Among Homeless Adults
Alcohol Use Disorder · Treatment · Homelessness
Primary: Satisfaction With App Treatment Messages — 3.9; 3.6; 3.8; 4.0 score on a scale
Phase 2 N=109 JBT-101 in Systemic Lupus Erythematosus (SLE)
Systemic Lupus Erythematosus · SLE · Lupus
Primary: Improvement in the Maximum Daily NRS-Pain Score at Day 84 — 6.3; 6.4; 6.0; 6.2 NRS Pain Score — p=0.4190
Phase 2 N=12 Safety and Dose-Finding Study of DTX401 (AAV8G6PC) in Adults With Glycogen Storage Disease Type Ia (GSDIa)
GSD1
Primary: Number of Participants With Adverse Events (AEs) Treatment-Emergent AEs (TEAEs) Serious TEAEs, Discontinuations Due to TEAEs, and Dose-Limiting Toxicities (DLTs) — 1; 1…
Phase 4 N=21 HCV Treatment Immune Response With Grazoprevir/Elbasvir Before or After Renal Transplant
Hepatitis C · Renal Insufficiency, Chronic · Disorder of Transplanted Kidney
Primary: SVR 12 — 19; 1; 1 Participants
N/A N=100 Small-group, Virtual Program for Improving Symptoms and Distress Related to Hormonal Therapy for Breast Cancer Survivors
Breast Cancer · Adherence, Medication
Primary: Feasibility and Acceptability — 46; 47; 45; 47 Participants
Phase 2 N=16 Extension Study of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Duchenne Muscular Dystrophy
Primary: Change From Baseline in Time to Stand (TTSTAND) Versus Matched Historical Controls — 0.17; -0.38; -0.11; 0.69 seconds
Phase 3 N=30 Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe
Neovascular Age-related Macular Degeneration (nAMD)
Primary: Number of Participants With Ocular Treatment Emergent Adverse Events — 2 Participants
Phase 2 N=119 A Study of AZD8233 in Participants With Dyslipidemia
Dyslipidaemia
Primary: Change in Low-density Lipoprotein Cholesterol (LDL-C) at Week 12. — 0.978; 0.206; 0.270; 0.606 Ratio
Phase 3 N=174 Study Comparing Continuous Subcutaneous Infusion Of ABBV-951 With Oral Carbidopa/Levodopa Tablets For Treatment Of Motor Fluctuations In Adult Participants With Advanced Parkinson's Disease
Parkinson's Disease (PD)
Primary: Change From Baseline to Week 12 of the Double-Blind Treatment Period in Average Daily Normalized "On" Time Without Troublesome Dyskinesia — 0.97; 2.72 hours — p=0.0083